Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells

References

• Abate G, Mshana RN, Miorner H. 1998. Evaluation of a colorimetric assay based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2:1011–1016.
   PubMed Web of Science ®Google Scholar
• Alamgeer M, Ganju V, Watkins DN. 2013. Novel therapeutic targets in non-small cell lung cancer. Curr Opin Pharmacol 13:394–401.
   PubMed Web of Science ®Google Scholar
• Ambacher KK, Pitzul KB, Karajgikar M, Hamilton A, Ferguson SS, Cregan SP. 2012. The JNK- and AKT/GSK3beta- signaling pathways converge to regulate Puma induction and neuronal apoptosis induced by trophic factor deprivation. PLoS One 7:e46885.
   Google Scholar
• Barbarulo A, Iansante V, Chaidos A, Naresh K, Rahemtulla A, Franzoso G, Karadimitris A, Haskard DO, Papa S, Bubici C. 2013. Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma. Oncogene 32:4231–4242.
   PubMed Web of Science ®Google Scholar
• Ben-Ami I, Yao Z, Naor Z, Seger R. 2011. Gq protein-induced apoptosis is mediated by AKT kinase inhibition that leads to protein kinase C-induced c-Jun N-terminal kinase activation. J Biol Chem 286:31022–31031.
   Google Scholar
• Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, et al. 2009. Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106:16281–16286.
   PubMed Web of Science ®Google Scholar
• Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D. 1999. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol Cell Biol 19:1938–1949.
   PubMed Web of Science ®Google Scholar
• Bubici C, Papa S. 2014. JNK signalling in cancer: In need of new, smarter therapeutic targets. Br J Pharmacol 171:24–37.
   PubMed Web of Science ®Google Scholar
• Cagle PT, Allen TC. 2012. Lung cancer genotype-based therapy and predictive biomarkers: Present and future. Arch Pathol Lab Med 136:1482–1491.
   Google Scholar
• Casaletto JB, McClatchey AI. 2012. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer 12: 387–400.
   PubMed Web of Science ®Google Scholar
• Chetram MA, Hinton CV. 2012. PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res 32:190–195.
   PubMed Web of Science ®Google Scholar
• Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Baron A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA Jr. 2006. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 4:521–528.
   PubMed Web of Science ®Google Scholar
• Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A. 2007. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 26:2423–2434.
   PubMed Web of Science ®Google Scholar
• Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. 2003. MAPK pathways in radiation responses. Oncogene 22:5885–5896.
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069–1075.
   PubMed Web of Science ®Google Scholar
• Edwards A, Li J, Atadja P, Bhalla K, Haura EB. 2007. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 6:2515–2524.
   PubMed Web of Science ®Google Scholar
• Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. 2008. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504–514.
   PubMed Web of Science ®Google Scholar
• Jassem J, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ, Park K, Novello S, Strausz J, Gualberto A. 2010. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 28:7500.
   Google Scholar
• Kemper K, Versloot M, Cameron K, Colak S, de Sousa e Melo F, de Jong JH, Bleackley J, Vermeulen L, Versteeg R, Koster J, Medema JP. 2012. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. Clin Cancer Res 18:3132–3141.
   PubMed Web of Science ®Google Scholar
• Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman SM, Wistuba, II, Hong WK, Lee HY. 2012. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer 118:3993–4003.
   PubMed Web of Science ®Google Scholar
• Kurland JF, Voehringer DW, Meyn RE. 2003. The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis. J Biol Chem 278: 32465–32470.
   Google Scholar
• Liao Y, Hung MC. 2003. Regulation of the activity of p38 mitogen- activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. Mol Cell Biol 23:6836–6848.
   PubMed Web of Science ®Google Scholar
• Lundholm L, Haag P, Zong D, Juntti T, Mork B, Lewensohn R, Viktorsson K. 2013. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Cell Death Dis 4:e478.
   PubMed Web of Science ®Google Scholar
• Marampon F, Gravina GL, Di Rocco A, Bonfili P, Di Staso M, Fardella C, Polidoro L, Ciccarelli C, Festuccia C, Popov VM, Pestell RG, Tombolini V, Zani BM. 2011. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther 10:159–168.
   PubMed Web of Science ®Google Scholar
• McMullen M, Keller R, Sussman M, Pumiglia K. 2004. Vascular endothelial growth factor-mediated activation of p38 is dependent upon Src and RAFTK/Pyk2. Oncogene 23:1275–1282.
   PubMedGoogle Scholar
• Neal JW, Sequist LV. 2010. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol 11:36–44.
   PubMed Web of Science ®Google Scholar
• Norbury C, Blow J, Nurse P. 1991. Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J 10:3321–3329.
   PubMed Web of Science ®Google Scholar
• Obermann EC, Went P, Pehrs AC, Tzankov A, Wild PJ, Pileri S, Hofstaedter F, Dirnhofer S. 2005. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Oncol Rep 14:1461–1467.
   PubMed Web of Science ®Google Scholar
• Paolo M, Assunta S, Antonio R, Claudia SP, Anna BM, Clorinda S, Francesca C, Fortunato C, Cesare G. 2013. Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: Endless clinical challenge to KRAS-mutant NSCLC. Rev Recent Clin Trials 8:93–100.
   Google Scholar
• Provencio M, Sanchez A, Garrido P, Valcarcel F. 2010. New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer 11:91–97.
   PubMed Web of Science ®Google Scholar
• Raciti M, Lotti LV, Valia S, Pulcinelli FM, Di Renzo L. 2012. JNK2 is activated during ER stress and promotes cell survival. Cell Death Dis 3:e429.
   Google Scholar
• Roskoski R Jr. 2012. ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol Res 66:105–143.
   PubMed Web of Science ®Google Scholar
• Sato A, Sunayama J, Matsuda K, Seino S, Suzuki K, Watanabe E, Tachibana K, Tomiyama A, Kayama T, Kitanaka C. 2011. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells 29:1942–1951.
   PubMedGoogle Scholar
• Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, Chellappan SP. 2012. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer 11:73.
   PubMed Web of Science ®Google Scholar
• Sunayama J, Matsuda K, Sato A, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, Kitanaka C. 2010. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 28:1930–1939.
   PubMed Web of Science ®Google Scholar
• Toulany M, Rodemann HP. 2010. Membrane receptor signaling and control of DNA repair after exposure to ionizing radiation. Nuklearmedizin 49(Suppl. 1):S26–30.
   Google Scholar
• Toulany M, Lee KJ, Fattah KR, Lin YF, Fehrenbacher B, Schaller M, Chen BP, Chen DJ, Rodemann HP. 2012. Akt promotes post- irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Res 10:945–957.
   Google Scholar
• Tournier C. 2013. The 2 Faces of JNK Signaling in Cancer. Genes Cancer 4:397–400.
   PubMedGoogle Scholar
• Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J, Dennis PA. 2006. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 24:306–314.
   PubMed Web of Science ®Google Scholar
• Wei X, Ni S, Correll PH. 2005. Uncoupling ligand-dependent and -independent mechanisms for mitogen-activated protein kinase activation by the murine Ron receptor tyrosine kinase. J Biol Chem 280:35098–35107.
   Google Scholar
• Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galban S, Galban CJ, Ross BD, Lawrence TS, Rehemtulla A, Sebolt-Leopold J. 2012. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther 11:1193–1202.
   Google Scholar
• Vincent EE, Elder DJ, Thomas EC, Phillips L, Morgan C, Pawade J, Sohail M, May MT, Hetzel MR, Tavare JM. 2011. Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer 104:1755–1761.
   PubMed Web of Science ®Google Scholar
• Woodward WA, Bristow RG. 2009. Radiosensitivity of cancer- initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semin Radiat Oncol 19:87–95.
   PubMed Web of Science ®Google Scholar
• Yeung K, Carlson JJ. 2012. Clinical and economic review of erlotinib in non-small-cell lung cancer. Expert Rev Pharmacoecon Outcomes Res 12:411–423.
   PubMed Web of Science ®Google Scholar
• Yoon YK, Kim HP, Han SW, Oh do Y, Im SA, Bang YJ, Kim TY. 2010. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 49:353–362.
   PubMed Web of Science ®Google Scholar
• Zimmerman MA, Rahman NT, Yang D, Lahat G, Lazar AJ, Pollock RE, Lev D, Liu K. 2012. Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res 72:4724–4732.
   Google Scholar